Precision BioSciences, Inc. (NASDAQ:DTIL) Receives $32.25 Average PT from Brokerages

by · The Markets Daily

Precision BioSciences, Inc. (NASDAQ:DTIL – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $32.25.

Several equities analysts have recently commented on DTIL shares. HC Wainwright reaffirmed a “buy” rating on shares of Precision BioSciences in a research note on Monday, August 3rd. Oppenheimer assumed coverage on Precision BioSciences in a research report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 price target for the company. Wall Street Zen lowered Precision BioSciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Precision BioSciences in a report on Wednesday, August 5th.

Read Our Latest Analysis on Precision BioSciences

Precision BioSciences Price Performance

DTIL opened at $6.36 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 12.82 and a quick ratio of 12.82. The stock’s 50 day simple moving average is $7.46 and its 200 day simple moving average is $7.16. The firm has a market cap of $175.55 million, a price-to-earnings ratio of -2.27 and a beta of 1.24. Precision BioSciences has a 1 year low of $3.53 and a 1 year high of $9.62.

Precision BioSciences (NASDAQ:DTIL – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. As a group, analysts predict that Precision BioSciences will post -3.33 earnings per share for the current year.

Institutional Investors Weigh In On Precision BioSciences

A number of large investors have recently modified their holdings of DTIL. Octagon Capital Advisors LP increased its position in shares of Precision BioSciences by 16.6% during the first quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock valued at $12,302,000 after buying an additional 318,737 shares during the period. Empery Asset Management LP bought a new position in shares of Precision BioSciences in the 4th quarter worth approximately $9,130,000. Affinity Asset Advisors LLC purchased a new position in shares of Precision BioSciences in the 1st quarter valued at approximately $3,289,000. Corient Private Wealth LP boosted its position in shares of Precision BioSciences by 70.4% during the second quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock valued at $1,926,000 after purchasing an additional 101,206 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its position in shares of Precision BioSciences by 212.7% during the second quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock valued at $1,078,000 after purchasing an additional 93,258 shares in the last quarter. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

(Get Free Report)

See Also